Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Mayinglong Pharmaceutical Group Co's
Operating Income
for the
three
months ended in Mar. 2026 was ¥247 Mil. Mayinglong Pharmaceutical Group Co's Interest Expense for the
three
months ended in Mar. 2026 was ¥-1 Mil.
Mayinglong Pharmaceutical Group Co's interest coverage for the quarter that ended in Mar. 2026 was 225.32.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Mayinglong Pharmaceutical Group Co Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Mayinglong Pharmaceutical Group Co's Interest Coverage or its related term are showing as below:
SHSE:600993'
s Interest Coverage Range Over the Past 10 Years
Min: 24.69 Med: 65.5 Max: 105.85
Current: 93.77
SHSE:600993's Interest Coverage is ranked better than 78.02% of 687
companies
in the Drug Manufacturers industry
Industry Median: 12.75
vs SHSE:600993: 93.77
Mayinglong Pharmaceutical Group Co (SHSE:600993) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Mayinglong Pharmaceutical Group Co Interest Coverage Related Terms
Mayinglong Pharmaceutical Group Co Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Mayinglong Pharmaceutical Group Co Interest Coverage Chart
SHSE:600993 vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Mayinglong Pharmaceutical Group Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mayinglong Pharmaceutical Group Co Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mayinglong Pharmaceutical Group Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Mayinglong Pharmaceutical Group Co's Interest Coverage falls into.
Mayinglong Pharmaceutical Group Co Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mayinglong Pharmaceutical Group Co (SHSE:600993) has a Interest Coverage of 225.32 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Mayinglong Pharmaceutical Group Co and its competitors. This is 244% above median its historical median of 65.50. Over the past decade, Mayinglong Pharmaceutical Group Co's Interest Coverage has ranged from 24.69 to 105.85. According to the industry distribution chart, Mayinglong Pharmaceutical Group Co ranks #151 out of 687 companies in the Drug Manufacturers industry, placing it in the top 22%.
Is Mayinglong Pharmaceutical Group Co's Interest Coverage too high?
Mayinglong Pharmaceutical Group Co's current Interest Coverage of 225.32 is 244% above median its 10-year median of 65.50. Over the past 10 years, this metric has ranged from a low of 24.69 to a high of 105.85. The Drug Manufacturers industry median Interest Coverage is 12.75. Mayinglong Pharmaceutical Group Co's value of 225.32 is 1667.2% above this industry median. Based on the distribution chart, Mayinglong Pharmaceutical Group Co ranks #151 out of 687 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Mayinglong Pharmaceutical Group Co has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mayinglong Pharmaceutical Group Co's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Mayinglong Pharmaceutical Group Co ranks #151 out of 687 companies for Interest Coverage. This places Mayinglong Pharmaceutical Group Co in the top 22% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 12.75. Mayinglong Pharmaceutical Group Co's value of 225.32 is 1667.2% above this benchmark. Historically, Mayinglong Pharmaceutical Group Co's own Interest Coverage has ranged from 24.69 to 105.85 over the past decade. While the company's 10-year median is 65.50 vs. the industry median of 12.75, Mayinglong Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.75, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mayinglong Pharmaceutical Group Co's current Interest Coverage of 225.32 is 1667.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Mayinglong Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mayinglong Pharmaceutical Group Co's current Interest Coverage is 225.32, which is 244% above median its own 10-year median of 65.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayinglong Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Mayinglong Pharmaceutical Group Co (SHSE:600993) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥29.53, compared to a current price of ¥23.25 — trading 21.3% below its estimated fair value. The current Interest Coverage is 225.32, which is 244% above median its 10-year median of 65.50 and 1667.2% above the Drug Manufacturers industry median of 12.75. Mayinglong Pharmaceutical Group Co's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Mayinglong Pharmaceutical Group Co (SHSE:600993), the current Interest Coverage is 225.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mayinglong Pharmaceutical Group Co (SHSE:600993) Overvalued in 2026?
Based on GuruFocus' analysis, Mayinglong Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of ¥23.25 is trading 21.3% below its estimated GF Value™ of ¥29.53.
GuruFocus considers Mayinglong Pharmaceutical Group Co to be Modestly Undervalued.
Key valuation signals for SHSE:600993:
Interest Coverage: 225.32 (244% above median its 10-year median of 65.50)
GF Value™: ¥29.53 vs. price of ¥23.25 (21.3% below fair value)
Industry Position: 1667.2% above the Drug Manufacturers median (#151 of 687)
No single metric tells the full story. See the SHSE:600993 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mayinglong Pharmaceutical Group Co Business Description
Mayinglong Pharmaceutical Group Co Ltd is a China-based company mainly involved in pharmaceutical development, retailing and wholesaling. The company provides ointments, suppositories, and tablets for hemorrhoids.
92GF Score
Get the complete analysis for SHSE:600993
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600993 has been successfully added to your 
